 Home > Active Ingredient News > Antitumor Therapy > The European Union has approved the first-line treatment of imfinzi (durvalumab) for the widespread treatment of small cell lung cancer.

The European Union has approved the first-line treatment of imfinzi (durvalumab) for the widespread treatment of small cell lung cancer.

 Last Update: 2020-09-24
 Source: Internet
 Author: User

Tags

macrophage cell line

phase

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Widespread stage small cell lung cancer (extensive-stage cell lung cancer, ES-SCLC) accounts for about two-thirds of small cell lung cancer (small cell lung, SCLC), treatment mainly chemotherapy, auxiliary radiotherapy and other comprehensive treatment.
ES-SCLC is a highly invasive, rapidly deteriorating form of lung cancer that, although initially responded to chemotherapy, usually relapses, highlighting the urgent need for new treatments.
recently, AstraZeneca's Durvalumab has been approved by the European Union to treat adult patients with ES-SCLC with a variety of chemotherapy drugs.
in CASPIAN PHASE III clinical trials, Imfinzi combined chemotherapy first-line therapy showed significant overall lifetime (OS) benefits (13.0 months vs. 10.3 months) and an increase in objective remission rates (68 percent vs. 58 percent) compared to chemotherapy alone.
The first immunotherapy in patients with widespread small cell lung cancer that improves both survival and response rates," said Dave Fredrickson, executive vice president of Oncology at AstraZeneca.
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.